Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 8, 2016, Pages 1135-1144

  Staubach, P ^a   Metz, M ^b   Chapman Rothe, N ^c   Sieder, C ^c   Brautigam M ^c   Canvin, J ^d   Maurer, M ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

angioedema; chronic spontaneous urticaria; chronic urticaria quality of life questionnaire; omalizumab; quality of life

Indexed keywords

BETAMETHASONE; CLEMASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; OMALIZUMAB; PLACEBO; ANTIALLERGIC AGENT;

ADD ON THERAPY; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CHRONIC URTICARIA QUALITY OF LIFE QUESTIONNAIRE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CHRONIC DISEASE; CLINICAL TRIAL; DRUG RESISTANCE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOEDEMA; ANTI-ALLERGIC AGENTS; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OMALIZUMAB; QUALITY OF LIFE; RETREATMENT; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 84962717106     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12870     Document Type: Article

References (20)

1. Maurer M, Weller K, Bindsley-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011;66:317–330.
2. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000;105:664–672.
3. Weller K, Krause K, Ardelean E, Bräutigam M, Maurer M. Selected urticaria patients benefit from a referral to tertiary care centres–results of an expert survey. J Eur Acad Dermatol Venereol 2013;27:e8–16.
4. Staubach P, Eckhardt-Henn A, Dechene M, Vonend A, Metz M, Magerl M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006;154:294–298.
5. Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000;143:983–991.
6. Silvares MR, Fortes MR, Miot AH. Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil). Rev Assoc Med Bras 2011;57:577–582.
7. Zuberbier T, Aberer W, Asero R. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868–887.
8. McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs 2014;74:1693–1699.
9. 1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567–573.
10. Maurer M, Rosén KE, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924–935.
11. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101–109.
12. 1-antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015;135:925.
13. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202–209.
14. Mlynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW et al. The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009;64:927–936.
15. Baiardini I, Braido F, Bindsley-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 2011;66:840–844.
16. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 2012;67:1289–1298.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
18. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K et al. Development, validation, and initial results of the angioedema activity score. Allergy 2013;68:1185–1192.
19. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy 2008;63:777–780.
20. Büyüköztürk S, Gelincik A, Demirtürk M, Kocaturk E, Colakoğlu B, Dal M. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticarial patients: a real life survey. J Dermatol 2012;39:439–442.